GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

Four of the top 5 selling products of GSK are antibiotics (Augmentin, Duricef, Ceporex and Velosef). Two of them come from BMS. By having four well established - and relatively old - antibiotic ...

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.

For further results highlights, click. GlaxoSmithKline Pharma continued to benefit from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Moreover ...

GlaxoSmithKline said its key brands held ... and continued to stay in line with the respective category performance. Augmentin continues to be the leading brand in the overall Indian pharma ...